Controlling cancer pain: Is morphine the best we can do?

Summary Despite the existence of a family of 3 classical and one non-classical opioid receptor, morphine, acting at the MOP (μ) receptor remains the gold standard for use in cancer pain. The main thrust of opioid development has been to produce highly selective morphine like molecules but these prod...

Full description

Saved in:
Bibliographic Details
Published inTrends in anaesthesia & critical care Vol. 1; no. 5; pp. 227 - 229
Main Authors Dietis, N, Rowbotham, D.J, Lambert, D.G
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2011
Subjects
Anesthesia & Perioperative Care
Cancer pain
Critical Care
Morphine
Opioids
Cancer pain
Morphine
Opioids
Online AccessGet full text

Cover

More Information
Summary:Summary Despite the existence of a family of 3 classical and one non-classical opioid receptor, morphine, acting at the MOP (μ) receptor remains the gold standard for use in cancer pain. The main thrust of opioid development has been to produce highly selective morphine like molecules but these produce side effects (respiratory depression and arrest, constipation, nausea and vomiting, pruritis and tolerance). Tolerance is particularly troublesome as this leads to increased dosing and more side effects. Laboratory experiments suggest that simultaneous targeting of multiple members of the opioid family may be the way forward. For example disruption of DOP (δ) receptor activity reduces morphine tolerance. Rational design and evaluation of non-selective opioids might offer good quality analgesia, reduced side effects and an alternative to morphine.
ISSN:2210-8440
DOI:10.1016/j.tacc.2011.08.003